Are Statins Worth It? (Part 2)

In part two of his series on statins, Dr. Michael Greger examines the controversial issue of statin intolerance and the real risks versus benefits of these cholesterol-lowering drugs. He highlights a critical disconnect between clinical trial data—showing very low rates of muscle side effects—and real-world observational studies, which report rates up to 1 in 5 patients experiencing muscle symptoms. This discrepancy, he argues, stems from industry bias, selective reporting, and exclusion of at-risk patients from trials. When statin-intolerant individuals are re-challenged with placebo or the actual drug, roughly a third to half still report muscle pain, confirming that while many side effects may be psychosomatic, a significant number are genuine. The episode also explores broader concerns like fatigue and cognitive effects, finding little evidence of long-term brain harm but strong support for statins reducing dementia risk. Dr. Greger contrasts pharmaceutical approaches with lifestyle interventions, spotlighting the Lyon Diet Heart Study, which showed a plant-based Mediterranean diet reduced heart attack risk by 70%—surpassing drug outcomes. He concludes with a cost-benefit analysis, emphasizing statins’ affordability, effectiveness, and safety, particularly atorvastatin and rosuvastatin, while underscoring that diet remains a powerful, underappreciated tool in cardiovascular prevention.